Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application
Introduction Hyperthermia (HT) at temperatures between 39 °C and 44 °C is utilized as an adjunctive cancer therapy, serving as potent radio- and chemosensitizer. Its effectiveness in treating solid malignancies has been well established. This raises the question of whether HT can also benefit patien...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/02656736.2024.2418427 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560941127270400 |
|---|---|
| author | Moritz V. Scharr Frederik Damm Paul Krahl Anna Dieper Paraskevi D. Veltsista Alexander Hansch Marcus Beck Dominik Gerster Anna-Chiara Giovannelli Lars Bullinger Daniel Zips Pirus Ghadjar |
| author_facet | Moritz V. Scharr Frederik Damm Paul Krahl Anna Dieper Paraskevi D. Veltsista Alexander Hansch Marcus Beck Dominik Gerster Anna-Chiara Giovannelli Lars Bullinger Daniel Zips Pirus Ghadjar |
| author_sort | Moritz V. Scharr |
| collection | DOAJ |
| description | Introduction Hyperthermia (HT) at temperatures between 39 °C and 44 °C is utilized as an adjunctive cancer therapy, serving as potent radio- and chemosensitizer. Its effectiveness in treating solid malignancies has been well established. This raises the question of whether HT can also benefit patients with nonsolid tumors, such as lymphomas.Objective To provide an overview of the current literature on research involving the use of HT in the treatment of lymphomas.Material and Methods This systematic literature review was conducted following the PRISMA guidelines. For this purpose, a MeSH-term-defined literature search on MEDLINE (Pubmed) and Embase (Ovid) was conducted from June 25 to June 28, 2024. Included were in vitro studies on lymphoma cell lines and preclinical studies on animal models with lymphoma that were both treated with HT as monotherapy or HT in combination with another treatment, and studies on patients with lymphoma. Excluded were studies that used thermal ablation and hyperthermic perfusions.Results Thirty-nine studies were included, predominantly in vitro studies (n = 32) or studies on animal models (n = 5). The in vitro studies utilized HT either as monotherapy (n = 6), with substances that enhance HT efficacy (n = 18) or as a sensitizer for other treatments (n = 8). Additionally, two clinical case reports on the treatment of lymphoma patients were included.Conclusions In vitro results suggest that HT can have anticancer effects on lymphoma cells and may enhance existing treatments. These findings are supported by in vivo studies and case reports. However, additional clinical data are needed before translation into the clinic can be implemented. |
| format | Article |
| id | doaj-art-19fb9077debb4ee899831ca550d90dad |
| institution | Kabale University |
| issn | 0265-6736 1464-5157 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj-art-19fb9077debb4ee899831ca550d90dad2025-01-03T09:30:27ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572024-12-0141110.1080/02656736.2024.2418427Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical applicationMoritz V. Scharr0Frederik Damm1Paul Krahl2Anna Dieper3Paraskevi D. Veltsista4Alexander Hansch5Marcus Beck6Dominik Gerster7Anna-Chiara Giovannelli8Lars Bullinger9Daniel Zips10Pirus Ghadjar11Department of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyGerman Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyGerman Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyDepartment of Radiation Oncology, Charité – Universitätsmedizin Berlin corporate member of Free University Berlin and Humboldt University Berlin, Berlin, GermanyIntroduction Hyperthermia (HT) at temperatures between 39 °C and 44 °C is utilized as an adjunctive cancer therapy, serving as potent radio- and chemosensitizer. Its effectiveness in treating solid malignancies has been well established. This raises the question of whether HT can also benefit patients with nonsolid tumors, such as lymphomas.Objective To provide an overview of the current literature on research involving the use of HT in the treatment of lymphomas.Material and Methods This systematic literature review was conducted following the PRISMA guidelines. For this purpose, a MeSH-term-defined literature search on MEDLINE (Pubmed) and Embase (Ovid) was conducted from June 25 to June 28, 2024. Included were in vitro studies on lymphoma cell lines and preclinical studies on animal models with lymphoma that were both treated with HT as monotherapy or HT in combination with another treatment, and studies on patients with lymphoma. Excluded were studies that used thermal ablation and hyperthermic perfusions.Results Thirty-nine studies were included, predominantly in vitro studies (n = 32) or studies on animal models (n = 5). The in vitro studies utilized HT either as monotherapy (n = 6), with substances that enhance HT efficacy (n = 18) or as a sensitizer for other treatments (n = 8). Additionally, two clinical case reports on the treatment of lymphoma patients were included.Conclusions In vitro results suggest that HT can have anticancer effects on lymphoma cells and may enhance existing treatments. These findings are supported by in vivo studies and case reports. However, additional clinical data are needed before translation into the clinic can be implemented.https://www.tandfonline.com/doi/10.1080/02656736.2024.2418427Lymphomahyperthermiaelectromagnetic fieldscancertherapy |
| spellingShingle | Moritz V. Scharr Frederik Damm Paul Krahl Anna Dieper Paraskevi D. Veltsista Alexander Hansch Marcus Beck Dominik Gerster Anna-Chiara Giovannelli Lars Bullinger Daniel Zips Pirus Ghadjar Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application International Journal of Hyperthermia Lymphoma hyperthermia electromagnetic fields cancer therapy |
| title | Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application |
| title_full | Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application |
| title_fullStr | Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application |
| title_full_unstemmed | Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application |
| title_short | Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application |
| title_sort | review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application |
| topic | Lymphoma hyperthermia electromagnetic fields cancer therapy |
| url | https://www.tandfonline.com/doi/10.1080/02656736.2024.2418427 |
| work_keys_str_mv | AT moritzvscharr reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT frederikdamm reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT paulkrahl reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT annadieper reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT paraskevidveltsista reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT alexanderhansch reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT marcusbeck reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT dominikgerster reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT annachiaragiovannelli reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT larsbullinger reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT danielzips reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication AT pirusghadjar reviewofpreclinicaldataonhyperthermiatreatmentinlymphomasanditspotentialforclinicalapplication |